Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion

Journal of Clinical Pharmacology

Volumn 48, Issue 1, 2008, Pages 19-25

  McSwain, C Shane ^h   Benza, Ray ^a   Shapiro, Shelley ^b   Hill, Nicholas ^c   Schilz, Robert ^d   Elliott, C Gregory ^e   Zwicke, Dianne L ^f   Oudiz, Ronald J ^g   Staszewski, James P ^h   Arneson, Carl P ^h   Wade, Michael ^h   Zaccardelli, David ^h   McLaughlin, Vallerie ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f ST LUKE S MEDICAL CENTER   (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

^h UNITED THERAPEUTICS CORPORATION   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Pharmacokinetic; Prostacyclin; Pulmonary arterial hypertension (PAH); Treprostinil

Indexed keywords

ANTICOAGULANT AGENT; DIURETIC AGENT; PHOSPHODIESTERASE V INHIBITOR; UNIPROST;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE ESCALATION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; MULTICENTER STUDY; OPEN STUDY; PULMONARY HYPERTENSION; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, LIQUID; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIGOXIN; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MASS SPECTROMETRY; MIDDLE AGED; OXYGEN; REGRESSION ANALYSIS;

EID: 37349045123     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007309708     Document Type: Article

References (13)

1. Vane JR, Botting RM Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995 ; 75: 3A - 10A.
2. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 ; 327: 70-75.
3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 ; 334: 296-302.
4. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000 ; 132: 425-434.
5. Simonneau G., Barst RJ, Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 ; 165: 800-804.
6. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 ; 41: 293-299.
7. Tapson VF, Gomberg-Maitland M., McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006 ; 129: 683-688.
8. Laliberte K., Arneson C., Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004 ; 44: 209-214.
9. Remodulin ® (treprostinil sodium) [package insert]. Research Triangle Park, NC: United Therapeutics Corporation ; 2002.
10. Wade M., Baker FJ, Roscigno R., et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004 ; 44: 503-509.
11. Wade M., Baker FJ, Roscigno R., DellaMaestra W., Hunt TL, Lai AA Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol. 2004 ; 44: 83-88.
12. Skoro-Sajer N., Bonderman D., Wiesbauer F., et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2007 ; 5: 483-489.
13. Sitbon O., Manes A., Jais X., et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2007 ; 49: 1-5.